When cancer cells move from their initial location to the bones, they impair the normal activity of bone cells. This process is known as bone metastasis. It may result in hypercalcemia, spinal cord compression, discomfort, and fractures. Common causes include lung, prostate, and breast cancers. There are two types, osteoblastic (excess bone production) and osteolytic (bone destruction). Imaging and blood tests are used for diagnosis. Medicine, radiation, and surgery are used for therapy. The bone metastasis pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in the bone metastasis pipeline analysis include Eli Lilly and Company, Bayer, and Actuate Therapeutics Inc., among others.
Leading drugs currently in the pipeline include abemaciclib, Radium-223, others.
Advancements in novel antiviral therapies and immune-modulating agents are driving pipeline growth. Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Bone Metastasis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into bone metastasis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Bone Metastasis therapeutics. The bone metastasis report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The bone metastasis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with bone metastasis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to bone metastasis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The pathophysiology of bone metastasis involves tumor cells colonizing bone marrow, disrupting bone homeostasis through interactions with osteoclasts (bone-resorbing cells) and osteoblasts (bone-forming cells). This leads to a "vicious cycle" in which tumors release growth factors (e.g., TGF-β, IGF-1) that fuel tumor growth, while tumors secrete cytokines (e.g., PTHrP, IL-11) that further activate osteoclasts. Metastases can be osteolytic (excessive resorption, common in breast cancer) or osteoblastic (excessive bone formation, typical in prostate cancer). The tumor cells may lie dormant in marrow niches before reactivating. Bisphosphonates or denosumab are used to inhibit bone destruction.
The goals of treating bone metastases include reducing symptoms, maintaining quality of life, and avoiding skeletal issues. Bisphosphonates (zoledronic acid) and denosumab are examples of systemic treatments that prevent bone deterioration, lowering the likelihood of fractures and their associated pain. Radiation therapy reduces pain and controls tumors by focusing on specific lesions. Fractures or imminent fractures (such as spinal cord compression) are stabilized by surgery. Strontium-89 and samarium-153 are examples of radiopharmaceuticals that target certain bone lesions with radiation. While physical therapy promotes mobility, underlying malignancies are treated with analgesics, chemotherapy, and hormone treatment. Treatment regimens are customized based on the patient's health, lesion location, and kind of cancer.
About 68–75% of instances of advanced malignancies involve bone metastases, with breast, prostate, and lung cancers making up most of these cases. Bone metastases occur in around 70% of patients with advanced prostate or breast cancer. Each type of cancer has a different prevalence; lung cancer has the highest percentage upon diagnosis (18.05%). In 2008, about 280,000 people in the United States had bone metastases.
This section of the report covers the analysis of bone metastasis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total bone metastasis clinical trials.
The drug molecule categories covered under the bone metastasis pipeline analysis include small molecules, RNA-based therapies, peptides, biologics, and gene editing therapies. The bone metastasis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Bone Metastasis.
Capsid assembly modulators (CAMs) are emerging as promising agents in the bone metastasis pipeline. For example, HAP18, a small molecule assembly agonist, disrupts the HBV core protein dimer’s hydrogen bonding while stabilizing capsids. This dual action results in empty, defective capsids and impedes viral genome release, reducing the formation of new infectious particles.
The EMR report for the bone metastasis pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in bone metastasis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for bone metastasis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of bone metastasis drug candidates.
Abemaciclib by Eli Lilly and Company is in Phase 2 of a clinical trial for treating bone metastases. The trial assesses its efficacy in combination with endocrine therapy, focusing on disease progression and overall survival. Abemaciclib is a CDK4/6 inhibitor used in breast cancer treatment, aiming to prevent cancer cell growth. The study is industry-funded and currently active.
Radium-223, developed by Bayer, is in Phase 1 of a clinical trial for treating bone metastases. The trial evaluates its safety and efficacy, particularly in combination with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC). Radium-223 is a radiopharmaceutical that targets bone metastases, delivering localized radiation to cancer cells while minimizing damage to surrounding tissue.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Bone Metastasis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for bone metastasis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into bone metastasis collaborations, regulatory environments, and potential growth opportunities.
Hepatitis B Virus (HBV) Infection Drug Pipeline Analysis Report
Upto 30% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share